Stockscreener 앱 받기
6.68
1.18%
-0.08
전일 마감가:
$6.76
열려 있는:
$6.72
하루 거래량:
1.58M
Relative Volume:
0.90
시가총액:
$517.80M
수익:
$14.79M
순이익/손실:
$-102.44M
주가수익비율:
-2.1974
EPS:
-3.04
순현금흐름:
$-91.73M
1주 성능:
+15.37%
1개월 성능:
+37.59%
6개월 성능:
+108.10%
1년 성능:
-24.43%
1일 변동 폭
$6.6429
$7.12
1주일 범위
$5.74
$7.12
52주 변동 폭
$2.41
$10.37
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
SLDB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.68 | 482.92M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-26 | 개시 | Citigroup | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
Solid Biosciences Inc. Stock Analysis and ForecastExplosive capital gains - Autocar Professional
Is Solid Biosciences Inc. a good long term investmentFree Expert Stock Watchlist - Autocar Professional
Solid Biosciences Receives FDA Fast Track Designation for - GlobeNewswire
Solid Biosciences and the Breakthrough Potential of SGT-501 for CPVT: A Rare Disease Play with Explosive Upside - AInvest
Solid Bio gets FDA fast track status for heart disease drug - Seeking Alpha
Solid Bio Green on Fast Track Nod - Baystreet.ca
Solid Biosciences receives FDA Fast Track designation for CPVT therapy - Investing.com
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - Yahoo Finance
What drives Solid Biosciences Inc. stock priceFree Trading Psychology Coaching - Autocar Professional
Cantor Fitzgerald Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
What analysts say about Solid Biosciences Inc. stockFree Smart Trading Workshop - jammulinksnews.com
Solid Biosciences (SLDB) Soars 8.76% on FDA Approval - AInvest
Solid Biosciences Inc. shares rise 3.29% premarket after Senti Bio's presentation at BioScience Forum. - AInvest
Cantor Fitzgerald reiterates Overweight rating on Solid Biosciences stock By Investing.com - Investing.com Canada
Solid Biosciences stock rating reiterated at Market Outperform by JMP - Investing.com Canada
What institutions are buying Solid Biosciences Inc. stock nowSteady Income Ideas - beatles.ru
Solid Biosciences’ SWOT analysis: gene therapy stock shows promise amid challenges - Investing.com Nigeria
Citi maintains Buy rating on Solid Biosciences stock amid Elevidys safety concerns - Investing.com Canada
Why Solid Biosciences Inc. stock attracts strong analyst attentionSolid Return Trade Selections - beatles.ru
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
What makes Solid Biosciences Inc. stock price move sharplyFree Investment Group - beatles.ru
Cantor Fitzgerald Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade) - Seeking Alpha
Truist Financial Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm - The Victoria Advocate
For Patients - Solid Biosciences
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.32%
1.57%
자본화:
|
볼륨(24시간):